340TiPA multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection.

Autor:	Yan, S1 (AUTHOR), Zhang, Y2 (AUTHOR), Bi, X1 (AUTHOR), Zhao, J3 (AUTHOR), Du, S4 (AUTHOR), Huang, Z3 (AUTHOR), Liu, D5 (AUTHOR), Li, Z1 (AUTHOR), Zhou, J1 (AUTHOR), Cai, J1 (AUTHOR), Zhao, H1 (AUTHOR)
Zdroj:	Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu